Baillie Gifford & Co. Has $1.18 Million Holdings in Alector, Inc. (NASDAQ:ALEC)

Baillie Gifford & Co. reduced its holdings in Alector, Inc. (NASDAQ:ALEC) by 19.3% during the 2nd quarter, Holdings Channel reports. The institutional investor owned 260,442 shares of the company’s stock after selling 62,387 shares during the quarter. Baillie Gifford & Co.’s holdings in Alector were worth $1,182,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the business. Susquehanna Fundamental Investments LLC acquired a new position in shares of Alector during the 1st quarter worth approximately $760,000. Vanguard Group Inc. lifted its stake in Alector by 12.0% in the first quarter. Vanguard Group Inc. now owns 4,912,578 shares of the company’s stock valued at $29,574,000 after acquiring an additional 526,037 shares during the last quarter. Acadian Asset Management LLC grew its position in shares of Alector by 211.6% in the 1st quarter. Acadian Asset Management LLC now owns 444,647 shares of the company’s stock valued at $2,675,000 after acquiring an additional 301,936 shares during the period. Swiss National Bank increased its stake in shares of Alector by 6.5% during the 1st quarter. Swiss National Bank now owns 131,900 shares of the company’s stock worth $794,000 after purchasing an additional 8,000 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Alector by 3.6% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 61,239 shares of the company’s stock worth $489,000 after purchasing an additional 2,120 shares during the last quarter. 85.83% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts recently commented on ALEC shares. HC Wainwright reiterated a “buy” rating and set a $35.00 price target on shares of Alector in a report on Thursday, June 20th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Alector in a research note on Monday, July 29th. One investment analyst has rated the stock with a sell rating and five have issued a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $14.67.

Insider Activity

In related news, Director Paula Hammond sold 10,500 shares of the company’s stock in a transaction dated Monday, August 12th. The shares were sold at an average price of $5.06, for a total transaction of $53,130.00. Following the completion of the sale, the director now owns 60,209 shares of the company’s stock, valued at $304,657.54. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other news, Director Paula Hammond sold 10,500 shares of the company’s stock in a transaction that occurred on Monday, August 12th. The shares were sold at an average price of $5.06, for a total transaction of $53,130.00. Following the completion of the sale, the director now owns 60,209 shares of the company’s stock, valued at approximately $304,657.54. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Arnon Rosenthal sold 25,135 shares of the business’s stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $4.80, for a total value of $120,648.00. Following the transaction, the chief executive officer now directly owns 1,975,245 shares of the company’s stock, valued at approximately $9,481,176. The disclosure for this sale can be found here. In the last three months, insiders sold 50,595 shares of company stock worth $245,586. 9.10% of the stock is currently owned by company insiders.

Alector Stock Performance

NASDAQ:ALEC opened at $5.31 on Monday. The firm has a market cap of $511.80 million, a price-to-earnings ratio of -3.85 and a beta of 0.72. Alector, Inc. has a 52 week low of $3.66 and a 52 week high of $8.90. The firm’s 50-day simple moving average is $5.19 and its 200 day simple moving average is $5.53.

Alector (NASDAQ:ALEC) last issued its quarterly earnings results on Wednesday, August 7th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.49) by $0.09. The business had revenue of $15.08 million during the quarter, compared to analysts’ expectations of $16.04 million. Alector had a negative return on equity of 71.80% and a negative net margin of 125.11%. During the same period in the previous year, the company posted $0.02 earnings per share. Sell-side analysts anticipate that Alector, Inc. will post -1.93 EPS for the current year.

Alector Company Profile

Alector, Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.